Publication | Closed Access

Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients

MedicineCystic Fibrosis PatientsPulmonary ExacerbationsPulmonary PharmacologyPulmonary FibrosisDaily AmikacinPulmonary MedicineAntimicrobial ChemotherapyPharmacologyAntimicrobial Resistance